Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Be The Match BioTherapies expands fully characterized cord blood unit offerings 

By Brian Buntz | August 12, 2022

Be The Match BioTherapiesBe The Match BioTherapies now offers cryopreserved cord blood units (CBU) as allogeneic cell therapy starting material.

Potential applications of the CBUs include non-clinical, clinical and commercial use.

The company’s registry has more than 266,000 fully-characterized CBUs from domestic cord blood banks.

Be The Patch offers comprehensive characterization information about CBUs to identify therapy-matched units.

Donna Regan, senior director, customer Ready Products at NMDP/Be The Match, said in a news release that the company ensures that the CBUs conform to specific temperature and time guidelines.

The company touts its ability to serve as a single point of contact for CBUs, eliminating the need to qualify and contract with multiple cord blood banks across the country.

Be The Match BioTherapies’ registry includes more than 9 million potential blood stem cell donors in the U.S. Additionally, the company has access to as many as 39 million potential donors internationally.

Be the Match BioTherapies also provides follow-up tracking for the first two FDA-approved CAR-T therapies.

The company has forged or expanded several alliances in recent years.

In October 2020, the company expanded a collaboration with Gamida Cell (Nasdaq:GMDA) related to omidubicel, Gamida Cell’s cell therapy in Phase 3 clinical trials.

It announced a partnership with Lonza in late 2020 related to the cell and gene therapy supply chain.

In late 2021, Be The Match BioTherapies entered into a partnership with Vineti, which has developed a platform for cell and gene therapy supply chains.

Early this year, Be The Match BioTherapies announced that it had extended a collaboration with Atara Biotherapeutics (Nasdaq:ATRA) to offer healthy donor cells for Atara’s off-the-shelf T-cell immunotherapy platform for cancer and autoimmune disease patients.

The company also has a research partnership with the Center for International Blood and Marrow Transplant Research (CIBMTR).

Be The Match BioTherapies is a division of the National Marrow Donor Program/Be The Match.


Filed Under: Cell & gene therapy
Tagged With: Be The Match BioTherapies
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE